TP53 and P21 polymorphisms: Response to cisplatinum/paclitaxel-based chemotherapy in ovarian cancer

• Tipo: Artigo em Revista Científica Internacional
• Data: 2006

Autores

Santos, AM (Autor) Outra; Sousa, H (Autor) Outra; Portela, C (Autor) Outra; Pereira, D (Autor) Outra; Pinto, D (Autor) Outra; Catarino, R (Autor) Outra; Rodrigues, C (Autor) Outra; Araujo, AP (Autor) Outra; Lopes, C (Autor) ICBAS; Medeiros, R (Autor) ICBAS

Revista

Título: Biochemical and Biophysical Research Communications

Vol. 340

Páginas: 256-262

ISSN: 0006-291X

Editora: Elsevier

Indexação

ISI Web of Knowledge - 41 Citações

Scopus - 41 Citações

Classificação Científica

FOS: Ciências exactas e naturais > Ciências biológicas

Outras Informações

ID Authenticus: P-004-NAA

DOI: 10.1016/j.bbrc.2005.11.176

Abstract (EN): Ovarian cancer (OC) is the most lethal gynaecologic cancer and its standard treatment consists of platinum-based chemotherapy after cytoreductive surgery. The p53 protein plays a critical role on different cellular processes in response to DNA damage and it is responsible for transcriptional induction of the P21 gene. We have analysed 114 blood samples in order to investigate the effect of the TP53 codon 72 and the P21 3'UTR polymorphisms in response to cisplatinum/paclitaxel chemotherapy for OC treatment. The genotypes of the TP53 codon 72 and P21 3'UTR polymorphism were identified using AS-PCR and PCR-RFLP, respectively. Our results indicate that the TP53 P allele is associated with a worse prognosis (P = 0.011) while P21 polymorphism genotypes did not reveal any statistically significant result (P > 0.05). Furthermore, simultaneous carriers of the TP53 AA genotype and the P21 CC genotype demonstrate a longer progression-free interval (P = 0.020). This study suggests that the characterisation of a genetic profile can contribute to the definition of a better chemotherapy treatment.

Idioma: Inglês

Tipo (Avaliação Docente): Científica

Nº de páginas: 7